Strategic divestment Orifarm recently sold a portfolio of vitamins, minerals and supplements to STADA, indicating potential willingness to divest non-core assets. This presents an opportunity to engage on potential licensing, white-label, or distribution partnerships for remaining product lines or future collections.

European growth Leadership changes and board expansion in 2026 signal aggressive growth objectives across Europe. Approach can focus on scale-ready supply agreements, regional distribution expansion, and complementary brands to accelerate market penetration.

Leadership hires New CFO and CIO appointments, along with a Chief People Officer in 2023, suggest a focus on financial discipline, digital transformation, and talent strategy. Target opportunities around ERP, analytics, supply chain optimization, and cost-conscious procurement solutions.

Wholesale and hospitals Orifarm serves wholesalers, pharmacies, hospitals and patients, indicating multi-channel distribution readiness. Propose value-add solutions in regulatory compliance, serialization, inventory optimization, and cross-channel forecasting to support expanding access.

Technology stack Adoption of cloud, automation, and analytics tools (Azure/GCP, Apache Spark, UiPath, ServiceNow) suggests receptiveness to digital transformation. Opportunities exist for enterprise-grade data platforms, RPA-enabled procurement workflows, and secure IT/security services aligned with their scale.